STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease

Argenx, a biotechnology company, has reported a setback in the development of its drug Vyvgart for treating Sjögren's disease, a chronic autoimmune disorder. The Phase 3 trial results showed that Vyvgart did not outperform a placebo.